Skip to content

Oncopeptides complete first sales of Pepaxti in Greece

STOCKHOLM – June 19, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece.

Since receiving the approval of Pepaxti in the European Union and countries in the European Economic Area in August 2022, Oncopeptides have been focusing its launch efforts on Germany while also working to gain market access in other European countries.

“Although still at an early stage, I am happy that we now can supply in Greece and make a difference to patients there with a high unmet need,” says Monica Shaw, CEO of Oncopeptides. “As we work to launch across Europe we need to assess every country individually to find the optimal way to ensure we can start to sell and patients can get access to Pepaxti. We are happy to partner with Ariti S.A. in Greece, as they have a solid experience in multiple myeloma including close relationships with healthcare professionals in the market and good understanding of how to ensure timely access to the drugs within rare diseases such as Pepaxti.”

In her recent presentation at the company´s Annual General Meeting, Monica Shaw outlined commercial opportunities for Oncopeptides in Europe. You can find a video of the presentation on Oncopeptides website.

For more information including a Q&A for investors, please visit our website.

For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
Cell phone: +46 76 229 38 68

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see:

Source: Oncopeptides